Anaplastic Glioma Clinical Trial
— HYPONCOOfficial title:
Hypoxia Diagnosis and Evaluation Using F-MISO PET and Biomarkers in Brain Tumors
Background :
In malignant gliomas, hypoxia is associated with tumour angiogenesis and tumour progression.
This multidisciplinary preclinical and clinical project aims to validate the use of
18F-FMISO as a hypoxic marker for diagnosis, treatment and follow-up of malignant gliomas.
Indeed, non-invasive methods of imagery such as Positron Emission Tomography (PET) and
biological methods (after surgical resection) to detect the endogenous expression of factors
induced by the hypoxia would allow to identify hypoxic areas. Identifying, with accuracy,
the hypoxic areas could allow the clinicians to evaluate the response to the anti-angiogenic
agents (preliminary validation in the preclinical project) and to optimize the combination
of the anti-VEGF treatments with other conventional therapeutic approaches (radiotherapy,
chemotherapy or other molecules).
Research project :
This research project includes 3 steps : first the investigators will establish the
18F-FMISO production technique for clinical application at CYCERON PET center. The second
step consists in the preclinical validation of 18F-FMISO as a hypoxic marker and as a
powerful tool for evaluating the therapeutical efficiency of anti-angiogenic treatment
(sutent) in experimental rat gliomas. The third step is the clinical trial HypOnco. This
research proposal aims to develop and use non invasive imaging methods (18F-FMISO with PET)
and biological methods (after surgical resection) to detect hypoxic (HIF1 and HIF2) and
angiogenic (VEGF and EPO) regions in different malignant gliomas with different degrees of
vascularization (15 patients with grade III gliomas and 15 patients with grade IV
glioblastomas). Within the same patient 18F-FMISO as a hypoxic index will be performed. A
magnetic resonance imaging examination (MRI) including perfusion sequences and MR
spectroscopy will also be assessed for each patient. Following this imaging protocol,
surgical resection will be performed allowing us to study expression of endogenous factors
induced by hypoxia and angiogenic factors by real time RT-PCR and in immunohistochemistry.
The data obtained will enable us to establish :
- a hypoxic index (18F-FMISO with PET).
- an index of hypoxic factor expression (HIFs)
- an angiogenic index (VEGF, EPO, vascular markers)
The investigators will characterize the links between these data and also with the following
parameters:
- clinical (age, Karnofsky performance status, survival)
- MR parameters included perfusion and spectroscopy
- histological (necrosis, cellular proliferation, atypical cell abnormalities,
vascularization).
Expected results and clinical advantages
- To establish the 18F-FMISO production technique
- To propose the 18F-FMISO as a non-invasive marker for efficacy of antiangiogenic
treatment in a preclinical study.
- To define the relationship between the 18F-FMISO uptake and tumour grade, patient
survival, tumour recurrence, expression of hypoxic and angiogenic factors and tumour
vascularisation.
- To provide a hypoxic index in cerebral tumours from 18F-FMISO PET, allowing diagnosis
and prognosis improvement for optimal treatment orientation and strategy.
In the field of the clinical applications, this tool will allow to :
- Optimize radiotherapy treatment by identifying with accuracy, using 18F-FMISO PET, the
most hypoxic areas which are also the most radio resistant.
- Evaluate antiangiogenic therapy efficacy
| Status | Completed |
| Enrollment | 39 |
| Est. completion date | July 2012 |
| Est. primary completion date | June 2012 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - adults aged >= 18 years - KPS >= 70% - must have the understanding and ability to sign an informed consent document - be male or non-pregnant - non-lactating females - Patients who are fertile must agree to use an effective method of contraception during participation in the study - the following laboratory results : absolute neutrophil count >= 1500 cells/µl, platelet count >= 100,000 cells/µl, SGOT <= 2.5 x ULN, serum creatinine <= 1.5 x ULN Exclusion Criteria: - contraindication to surgery - concomitant radio-, chemo-, or immunotherapy - known diagnosis of Human Immunodeficiency Virus (HIV) infection - patient with hepatitis B or C - diabetic patient - patient with kidney or liver deficiency |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Country | Name | City | State |
|---|---|---|---|
| France | Caen University Hospital | Caen |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Caen |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | hypoxia volume (HV) and degree (maximum ratio [Rmax]) defined from 18F-FMISO uptake rates | determine, in vivo, the hypoxic character of tumours from a PET biomarker. Tumoral hypoxia will be characterized by hypoxia volume (HV) and degree (maximum ratio [Rmax]) defined from 18F-FMISO uptake rates characterize the link between the tumoral hypoxia and the hypoxic and angiogenic factor expressions that favour vascular neoformation and proliferation feeding tumoral cells |
PET 18F-MISO between Day 1 & Day 7 | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00613093 -
Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma
|
Phase 2 | |
| Completed |
NCT01434602 -
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT00555399 -
Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04482933 -
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
|
Phase 2 | |
| Completed |
NCT00009035 -
Natural History of Patients With Brain and Spinal Cord Tumors
|